GE HealthCare Stock Jumps 5% After RBC Says the Selloff Went Too Far: What an $80 Target Means for Investors

Key Stats for GE Healthcare Stock

• Current Price: $63.72
• Target Price (Mid): ~$85
• Street Target: ~$80
• Potential Total Return: ~34%
• Annualized IRR: ~7% / year
• Earnings Reaction: +2.28% (4/29/26)
• Max Drawdown: (32.53%) (4/29/26)

Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>

What Happened?

GE HealthCare Technologies (GEHC) spent most of 2026 as a stock that few investors wanted to defend. It sat near three-year lows, down nearly 30% from its 52-week high of $89.77, with the market treating a slow-growth imaging company as a value trap. Then on June 23, the shares jumped 5.08% to close at $63.72. The catalyst was not earnings. It was one analyst arguing that the punishment no longer fit the business.

That analyst was RBC Capital Markets, which initiated coverage with an Outperform rating and an $80 price target. RBC’s case is blunt: at roughly 11x its 2027 earnings, GE HealthCare carries a risk-reward profile the share price does not reflect. The firm credited stronger commercial execution since the 2023 spinoff from General Electric for a backlog that now sits near $22 billion, roughly a full year of expected sales.

That backlog is the heart of the disagreement. Bulls see a record order pipeline priced as if none of it converts to revenue. Bears see two straight years of low-single-digit organic growth, an inflation-driven guidance cut, and a shrinking China business. The question the market cannot yet answer: is 2026 the trough before a reacceleration, or the new normal for a company growing slower than its peers?

See historical and forward estimates for GE Healthcare stock (It’s free!) >>>

Why the Stock Was So Beaten Down

The damage traces to one quarter. On April 29, GE HealthCare reported first-quarter results and cut its full-year outlook, and the stock bottomed at a 32.53% drawdown that same day. Revenue held up, but costs did not. At the Jefferies Global Healthcare Conference on June 3, CFO James Saccaro flagged about $250 million in gross inflation exposure for the year, spanning memory chips, oil and freight, and commodities like rare earth elements. The company trimmed full-year adjusted EPS guidance by roughly $0.15.

Saccaro framed it as prudence. “We don’t like to adjust guidance,” he said. “But sometimes it’s required and the appropriate thing to do as was the case here.” He added a detail the market may have underweighted: because orders carry supplier-borne price risk once booked, this year’s modest $0.06 price offset is not a ceiling, and a “much more significant price impact next year” is coming as costs flow into new pricing.

The Product Engine the Bears Keep Ignoring

The demand side never broke. GE HealthCare posted a book-to-bill ratio of 1.07x in the first quarter, meaning it booked more orders than it billed, and its $21.8 billion backlog stands at a record. Almost none of that came from new products. Saccaro said the quarter ran on “existing products on the market and commercial execution versus new products and new innovation, which will benefit future quarters.”

That future wave is large. Photon counting CT, a scanning technology that captures sharper spectral and spatial detail in a single image, and total body PET, which images the entire body at once, both open markets GE HealthCare does not serve today. Saccaro called them a “blue ocean.” The June 4 FDA clearance for MIM Contour ProtégéAI+ 2.0, an AI tool that automates organ tracing for radiation therapy planning, added another piece to the oncology software stack and helped fuel the late-June rally.

Then there is Flyrcado, a cardiac PET agent that measures blood flow to the heart. Management reaffirmed confidence in topping $500 million in revenue by 2028 and disclosed that the product moved from a roughly $25 million run rate in the first quarter to a $50 million annual run rate in the second. “It’s clear clinicians love the image quality,” Saccaro said, describing the remaining friction as workflow, not clinical.

How GEHC Stacks Up on Valuation

GE HealthCare trades at 9.64x next-twelve-months EV/EBITDA and 12.78x NTM P/E, both near post-spinoff lows. For a business with a 39.1% gross margin and a 13.5% ROIC, that is a distressed multiple.

The tension is unresolved. The bull view rests on backlog conversion and margin recovery as pricing kicks in through 2027. The bear view rests on organic growth stuck at 3% to 4%, China modeled down again this year, and tariff policy unsettled into a July expiration. Saccaro declined to promise China’s growth this year, expecting only that the market “normalize in the coming years.” The valuation is cheap because the growth is slow. Whether the product cycle changes that math in 2027 is what the market will not yet pay for.

See how GE Healthcare performs against its peers in TIKR (It’s free!) >>>

TIKR Advanced Model Analysis

• Current Price: $63.72
• Target Price (Mid): ~$85
• Potential Total Return: ~34%
• Annualized IRR: ~7% / year

See analysts’ growth forecasts and price targets for GE Healthcare stock (It’s free!) >>>

TIKR’s mid-case model, realized at the end of 2030, targets a fair value of around $85, implying a total return near 34% and an annualized IRR of roughly 7%. The mid case fits because it assumes neither that the product cycle fails nor that every launch hits its ceiling.

The two revenue CAGR drivers are Pharmaceutical Diagnostics volume as Flyrcado scales toward $500 million by 2028, and the new imaging cycle opening untapped markets. The margin driver is the pricing and cost reset management expected in 2027. The primary risk is growth staying near 3% to 4% while China and tariffs weigh, keeping the multiple compressed.

The upside: if backlog converts and margins recover, the stock rerates toward the mid-$80s. The downside: if growth stays slow and inflation lingers, GEHC compounds slowly from a low-double-digit multiple.

Conclusion

The signal to watch is margin recovery in the second half. Management has promised to offset more than half the inflation hit through pricing and cost actions, and the next reading comes with second-quarter results. If margins firm and the company holds the line on costs, RBC’s case that the selloff overshot gains support. If margins keep slipping, the cheap multiple starts to look deserved. Saccaro also promised a fresh Flyrcado dose update in July, a second tell on whether the product cycle is ramping on schedule. The story turns on the numbers, not the next analyst note.

See what stocks billionaire investors are buying so you can follow the smart money with TIKR.

Should You Invest in GE Healthcare?

The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.

Pull up GE Healthcare, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.

You can build a free watchlist to track GE Healthcare alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.

Analyze GE Healthcare on TIKR Free →

Looking for New Opportunities?

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!